

RECEIVED
CENTRAL FAX CENTER

APR 28 2006

FACSIMILE TRANSMITTAL

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Telephone: (510) 597-6502
Facsimile Number: (510) 597-6610

Date: Friday, April 28, 2006

To: Commissioner for Patents
United States Patent and Trademark Office

Facsimile No. 1-571-273-8300

From: Gary R. Fabian, Reg. No. 33,875 *GRF 28 Apr 2006*

Re: Serial No. 09/410,462 (Onyx Ref. 1046.ORD)

Message: Transmitted herewith for filing in the above-referenced application
are the following documents:

1. Transmittal;
2. Response to Non-Compliant Amendment, including the section titled
"Amendments to the Claims (including a complete listing of the claims); and
3. Certificates of Facsimile Transmission.

THE ATTACHED DOCUMENTS ARE TO BE MADE OF OFFICIAL RECORD

Total number of pages, including this cover sheet: 11 (Eleven)

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of the above message or the accompanying documents is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile, and mail the original to us at the above address. Thank you.

Please contact us at (510) 597-6502 if you have any problems receiving this transmission.

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

Gary R. Fabrin
Signature

28 Apr 2006

Date of Transmittal

RECEIVED
CENTRAL FAX CENTER

APR 28 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Williams, A., et al.	Confirmation No. 6889
Serial No.: 09/410,462	Art Unit: 1635
Filing Date: 1 October 1999	Examiner: J.E. Angell
Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS	

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

1. Transmittal;
2. Response to Notice of Non-Compliant Amendment, including the section titled "Amendments to the Claims (including a complete listing of the claims); and
3. Certificate of Transmission by Facsimile.

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

Authorization to Charge Deposit Account.

No additional fees are believed due. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 28 Apr 2006

By :

Gary R. Fabian
Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610

RECEIVED
CENTRAL FAX CENTER

APR 28 2006

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

Gary R. Fabian
Signature28 Apr 2006
Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Williams, A., et al.	Confirmation No. 6889
Serial No.: 09/410,462	Art Unit: 1635
Filing Date: 1 October 1999	Examiner: J.E. Angell
Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS	

Response to Notice of Non-Compliant Amendment

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

This is in response to the Notice of Non-Compliant Amendment, mailed 5 April 2006, in the above-referenced application. This response is being filed within ONE MONTH of the mailing date of the final Office action (i.e., before 5 May 2006). No additional fee is believed due; however, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the issue fee.

Reconsideration of the application in view of the following amendments and remarks is respectfully requested.